Pseudo-random generator - Patient demographics and characteristics by treatment group
| |
|
Control group (n=81144) |
Chloroquine (n=1868) |
Chloroquine with macrolide (n=3783) |
Hydroxychloroquine (n=3016) |
Hydroxychloroquine with macrolide (n=6221) |
| Age, years |
53.6 (17.6) |
55.1 (18.0) |
54.9 (17.7) |
55.1 (17.9) |
55.2 (17.7) |
| BMI, kg/m² |
27.4 (5.4) |
27.8 (6.1) |
28.2 (5.8) |
28.4 (5.9) |
28.5 (5.9) |
| Sex |
|
Female |
37716 (46.5%) |
845 (45.2%) |
1718 (45.4%) |
1388 (46.0%) |
2759 (44.3%) |
|
Male |
43428 (53.5%) |
1023 (54.8%) |
2065 (54.6%) |
1628 (54.0%) |
3462 (55.7%) |
| Race or ethnicity |
|
White |
54403 (67.1%) |
1201 (64.3%) |
2418 (63.9%) |
2074 (68.8%) |
4124 (66.3%) |
|
Black |
7519 (9.3%) |
203 (10.9%) |
369 (9.8%) |
287 (9.5%) |
676 (10.9%) |
|
Hispanic |
4943 (6.1%) |
108 (5.8%) |
273 (7.2%) |
194 (6.4%) |
460 (7.4%) |
|
Asian |
11504 (14.2%) |
301 (16.1%) |
603 (15.9%) |
366 (12.1%) |
745 (12.0%) |
|
Native American |
922 (1.1%) |
19 (1.0%) |
37 (1.0%) |
33 (1.1%) |
68 (1.1%) |
|
Other |
1853 (2.3%) |
36 (1.9%) |
83 (2.2%) |
62 (2.1%) |
148 (2.4%) |
| Comorbidities |
|
Coronary artery disease |
10076 (12.4%) |
284 (15.2%) |
515 (13.6%) |
421 (14.0%) |
841 (13.5%) |
|
Congestive heart failure |
1949 (2.4%) |
50 (2.7%) |
103 (2.7%) |
78 (2.6%) |
188 (3.0%) |
|
Arrhythmia |
2861 (3.5%) |
63 (3.4%) |
126 (3.3%) |
108 (3.6%) |
223 (3.6%) |
|
Diabetes |
11058 (13.6%) |
258 (13.8%) |
584 (15.4%) |
447 (14.8%) |
913 (14.7%) |
|
Hypertension |
21437 (26.4%) |
560 (30.0%) |
1095 (28.9%) |
891 (29.5%) |
1827 (29.4%) |
|
Hyperlipidaemia |
25538 (31.5%) |
607 (32.5%) |
1164 (30.8%) |
941 (31.2%) |
1948 (31.3%) |
|
COPD |
2647 (3.3%) |
55 (2.9%) |
144 (3.8%) |
111 (3.7%) |
220 (3.5%) |
|
Current smoker |
7884 (9.7%) |
190 (10.2%) |
428 (11.3%) |
342 (11.3%) |
644 (10.4%) |
|
Former smoker |
14049 (17.3%) |
321 (17.2%) |
648 (17.1%) |
509 (16.9%) |
1026 (16.5%) |
|
Immunocompromised |
2416 (3.0%) |
53 (2.8%) |
122 (3.2%) |
90 (3.0%) |
187 (3.0%) |
| Baseline disease severity |
|
qSOFA <1 |
67316 (83.0%) |
1530 (81.9%) |
3051 (80.7%) |
2477 (82.1%) |
4994 (80.3%) |
|
SPO₂ <94% |
7721 (9.5%) |
209 (11.2%) |
413 (10.9%) |
323 (10.7%) |
651 (10.5%) |
| Outcomes |
|
De-novo ventricular arrhythmia |
226 (0.3%) |
81 (4.3%) |
246 (6.5%) |
184 (6.1%) |
502 (8.1%) |
|
Non-ICU length of stay, days |
9.1 (6.4) |
8.8 (6.2) |
9.0 (6.6) |
8.9 (6.2) |
9.1 (6.7) |
|
ICU length of stay, days |
2.6 (5.0) |
4.3 (6.8) |
4.9 (8.1) |
4.3 (6.8) |
4.7 (7.8) |
|
Total length of stay, days |
11.7 (8.4) |
13.2 (9.1) |
13.8 (11.0) |
13.2 (9.3) |
13.8 (10.7) |
|
Mechanical ventilation |
6278 (7.7%) |
403 (21.6%) |
814 (21.5%) |
616 (20.4%) |
1243 (20.0%) |
|
Mortality |
7530 (9.3%) |
307 (16.4%) |
839 (22.2%) |
543 (18.0%) |
1479 (23.8%) |
|
Ventilator or mortality |
10703 (13.2%) |
531 (28.4%) |
1288 (34.0%) |
877 (29.1%) |
2120 (34.1%) |